In Vivo Stimulation of Vascular Plasminogen Activator Inhibitor-1 Production by very Low-Density Lipoprotein Involves Transcription Factor Binding to a VLDL-Responsive Element

Wolfgang Dichtl; Mikko P. S. Ares; Maria Stollenwerk; Cecilia M. Giachelli; Marta Scatena; Anders Hamsten; Per Eriksson; Jan Nilsson

doi:10.1055/s-0037-1614091

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2000; 84(04): 706-711
DOI: 10.1055/s-0037-1614091

Review Article

Schattauer GmbH

In Vivo Stimulation of Vascular Plasminogen Activator Inhibitor-1 Production by very Low-Density Lipoprotein Involves Transcription Factor Binding to a VLDL-Responsive Element

Authors

Wolfgang Dichtl

¹From the Wallenberg Laboratory, Department of Medicine, Malmö University Hospital, Lund University, Sweden

²King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden

³Department of Medicine, Division of Cardiology, University Hospital of Innsbruck, Austria; and
Mikko P. S. Ares

¹From the Wallenberg Laboratory, Department of Medicine, Malmö University Hospital, Lund University, Sweden
Maria Stollenwerk

¹From the Wallenberg Laboratory, Department of Medicine, Malmö University Hospital, Lund University, Sweden
Cecilia M. Giachelli

⁴Department of Pathology, University of Washington, Seattle, USA
Marta Scatena

⁴Department of Pathology, University of Washington, Seattle, USA
Anders Hamsten

²King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
Per Eriksson

²King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
Jan Nilsson

¹From the Wallenberg Laboratory, Department of Medicine, Malmö University Hospital, Lund University, Sweden

Abstract

Summary

High plasma levels of plasminogen activator inhibitor-1 (PAI-1) are associated with an increased risk of cardiovascular disease. There is also a close relation between high plasma levels of PAI-1 and hypertriglyceridemia. Cell culture studies have shown that very low density lipoprotein (VLDL) increases the production and secretion of PAI-1 in endothelial cells and hepatocytes, suggesting a possible mechanism for this association. To determine whether VLDL stimulates PAI-1 production in vascular cells also in vivo, Sprague-Dawley rats were injected intravenously with 6 mg/kg of VLDL (derived from human subjects with type IV hyperlipidemia). Previous studies have demonstrated that this results in an accumulation of human VLDL in the aorta and other arteries followed by increased nuclear factor-kappa B (NF-κB) activation. Endothelial, but not smooth muscle cells, showed a basal PAI-1 mRNA and protein expression as assessed by in situ hybridization and immunohistochemistry, respectively. Six to twenty-four hours after the VLDL injection, lipoprotein particle accumulation was seen in the aortic wall, which was accompanied by increasing PAI-1 mRNA and protein expression in endothelial and smooth muscle cells. Within the rat PAI-1 promoter we identified a sequence located at −589 to −571 with 74% homology with the recently described VLDL responsive element in the human PAI-1 promoter and located adjacent to a 4-guanosine motif presumably corresponding to the human 4G/5G polymorphism. Transient transfection studies showed that VLDL exerts its stimulatory effects on rat PAI-1 gene expression in vascular cells by interaction with promoter sequences located within bp −656 and −505. Electrophoretic mobility shift assays showed that VLDL increases the binding of as yet incompletely characterized factors to this response element. Taken together these observations support a direct influence of VLDL on vascular PAI-1 gene expression in vivo. This stimulation is exerted on the level of PAI-1 gene transcription, and involves transcription factor binding to a VLDL responsive element adjacent to a 4G motif within the PAI-1 promoter.

Key words

Hypertriglyceridemia - plasminogen activator inhibitor-1 - VLDL-RE - NF-κB-like proteins

Volltext

Referenzen

References
1 Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 02: 3-9.
2 Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factor and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-63.
3 Huber K, Resch I, Stefenelli T, Lang I, Probst P, Kaindl F, Binder BR. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis. Thromb Haemost 1990; 63: 336-9.
4 Suffredini AF, Harpel PC, Parillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
5 Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-52.
6 Latron Y, Chautan M, Anfosso F, Alessi C, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-9.
7 Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993; 13: 338-46.
8 Dichtl W, Stiko A, Eriksson P, Goncalves I, Calara F, Banfi C, Ares MPS, Hamsten A, Nilsson J. Oxidized LDL and lysophosphatidylcholine stimulate PAI-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 3025-32.
9 Allison BA, Nilsson L, Karpe F, Hamsten A, Eriksson P. Effects of native, triglyceride-enriched and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1354-60.
10 Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem 1991; 268: 2459-65.
11 Metha J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentration. J Am Coll Cardiol 1987; 09: 263-8.
12 Juhan-Vaque I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab 1987; 13: 331-6.
13 Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 01: 2-14.
14 Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-73.
15 Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27.
16 Sironi L, Mussoni L, Prati L, Baldassarre D, Camera M, Banfi C, Tremoli E. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996; 16: 89-96.
17 Björkegren J, Hamsten A, Milne RW, Karpe F. Alterations of VLDL composition during alimentary lipemia. J. Lipid Res 1997; 38: 301-14.
18 Nilsson L, Gåfvels M, Musakka L, Ensler K, Strickland D, Angelin B, Hamsten A, Eriksson P. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. J Lipid Res 1999; 40: 913-9.
19 Nilsson L, Banfi C, Diczfalusy U, Tremoli E, Hamsten A, Eriksson P. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1679-85.
20 de Man FH, de Beer F, van der Laarse A, Smelt AH, Havekes LM. Lipolysis of very low density lipoproteins by heparan sulfate proteoglycanbound lipoprotein lipase. J Lipid Res 1997; 38: 2465-72.
21 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
22 Eriksson P, Kallin B, van’t Hooft FM, Båvenholm P, Hamsten A. Allelespecific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
23 Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarctions in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997; 17: 33-7.
24 Eriksson P, Nilsson L, Karpe F, Hamsten A. A very low density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18: 20-6.
25 Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries S, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42.
26 Dichtl W, Nilsson L, Goncalves I, Ares MPS, Banfi C, Calara F, Hamsten A, Eriksson P, Nilsson J. Very low density lipoprotein activates nuclear factor-κB in endothelial cells. Circ Res 1999; 84: 1085-94.
27 Calara F, Dimayuga P, Niemann A, Shah PK, Cercek B, Witztum J, Palinski W, Thyberg J, Nilsson J, Regnström J. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998; 18: 884-93.
28 Johnson MR, Bruzdzinski CJ, Winograd SS, Gelehrter TD. Regulatory sequences and protein-binding sites involved in the expression of rat plasminogen activator inhibitor-1 gene. J Biol Chem 1992; 267: 12202-10.
29 Redgrave TG, Carlsson LA. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res 1979; 20: 217-29.
30 Lowry O, Rosenbrough N, Farr A, Randall R. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
31 Nicosia RF, Villaschi S, Smith M. Isolation and characterization of vasoformative endothelial cells from rat aorta. In Vitro Cell Dev Biol Anim 1994; 06: 394-9.
32 Nilsson J, Sjölund M, Palmberg L, Thyberg J, Heldin CH. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factorlike protein. Proc Natl Acad Sci USA 1985; 82: 4418-22.
33 Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed,. 1998. Cold Spring Harbour Laboratory; Cold Spring Harbour, New York.:
34 Alksnis M, Barkhem T, Strömstedt PE, Ahola H, Kutoh E, Gustafsson JÅ, Poellinger L, Nilsson S. High level expression of functional full length and truncated glucocorticoid receptor in Chinese hamster ovary cells. Demon-stration of ligand-induced down-regulation of expressed receptor mRNA and protein. J Biol Chem 1991; 266: 10078-85.
35 Henry M, Tregouët DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations. A family study with part of the stanislas cohort. Arterioscler Thromb Vasc Biol 1998; 18: 84-91.
36 Grenett H, Benza R, Fless G, Li XN, Davis G, Booyse F. Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells. Arterioscler Thromb Vasc Biol 1998; 18: 1803-9.
37 Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, Graninger DJ. Increased PAI-1 activity and PAI-1 antigen occuring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-β levels. Atherosclerosis 1998; 140: 45-53.
38 Sawa H, Lundgren C, Sobel BE, Fujii S. Increased intramural expression of plasminogen activator inhibitor type 1 after ballon injury: a potential progenitor of restenosis. J Am Coll Cardiol 1994; 24: 1742-8.
39 Proctor SD, Mamo JC. Retention of fluorescent-labeled chylomicron remnants within the intima of the arterial wall - evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998; 28: 497-503.
40 Bruzdzinski CJ, Riordan-Johnson M, Nordby EC, Suter S, Gelehrter TD. Isolation and characterization of the rat plasminogen activator inhibitor-1 gene. J Biol Chem 1990; 265: 2078-85.
41 Zhang WJ, Woitja J, Binder BR. Notoginsenoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-lethality in mice in vivo. Arterioscler Thromb Vasc Biol 1997; 17: 464-74.
42 Ferran C, Millan MT, Csizmadia V, Cooper JT, Brostjan C, Bach FH, Winkler H. Inhibition of NF-κB by pyrrolidine dithiocarbamate blocks endothelial cell activation. Biochem Biophys Res Commun 1995; 214: 212-23.
43 Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulba DC. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression. Circulation 1999; 100: 1369-73.
44 Banfi C, Mussoni L, Risé P, Cattaneo MG, Vicentini L, Battaini F, Galli C, Tremoli E. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor-1 in cultured HepG2 cells. Circ Res 1999; 85: 208-17.
45 Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-κB activation. EMBO J 1999; 18: 3044-53.
46 Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC. Transforming growth factor β is sequestered into an inactive pool by lipoproteins. J Lipid Res 1997; 38: 2344-52.
47 Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-100.
48 Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferatoractivated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-25.